The Public sector organization, National Dairy Development Board (NDDB), is like the proverbial 'Tortoise' racing past the 'Hare'; The Company has rolled out its batch of DNA Hepatitis -B Vaccine, which is slated to be far more cost-effective, as compared to the other brands in the market.
The vaccine, manufactured by Human Biologicals Institution (HBI) at its facility in Gachibowli, will be sold under the band name Elovac-B. NDDB, the parent company, owns Indian Immunologicals Ltd (IIL), of which Human Biologicals Institution forms a part.
Managing Director, IIL, Mr. K.V. Balasubramaniam, while addressing the media, indicated that the company is geared up to enable varieties of human vaccines, to combat measles, DPT, and TT. The good news is that the price of the Hepatitis-B Vaccine would be at least 40% lower than any of the currently available vaccines in the market.
IIL would be harnessing its extensive network of more than 2000 Abhay clinics to make its products available. Institutional channels will also be tapped to widen the reach of these vaccines.